RegulatoryJul 16, 2026, 04:37 PM
Cellyan Biotechnology Gets Nasdaq Extension for Minimum Bid Price
AI Summary
Cellyan Biotechnology Co., Ltd announced it received an additional 180-day grace period from Nasdaq to regain compliance with the minimum $1.00 closing bid price requirement. The company was initially notified of non-compliance on January 12, 2026, with an original deadline of July 13, 2026. The new extension grants the company until January 11, 2027, to meet the requirement by maintaining a bid price of at least $1.00 for ten consecutive business days. Cellyan Biotechnology plans to coordinate feasible solutions, including a potential reverse share split, to restore listing compliance.
Key Highlights
- Cellyan Biotechnology received an additional 180-day extension from Nasdaq.
- New deadline to regain minimum $1.00 bid price compliance is January 11, 2027.
- Company was initially notified of non-compliance on January 12, 2026.
- Original compliance deadline was July 13, 2026.
- Must maintain a closing bid price of at least $1.00 for 10 consecutive business days.
- Company intends to cure the deficiency, potentially via a reverse share split.
- Listing of Class A ordinary shares continues uninterrupted on Nasdaq under 'HKPD'.
Price Impact